SNN Stock Analysis: Smith & Nephew SNATS | NYSE

Knee Replacement, Hip Implants, Arthroscopic Instruments, Wound Care

Total Rating 45

Safety 89

Buy Signal -0.10

Medical Devices
Industry Rotation: +1.3

Market Cap: 11.1B
Avg Turnover: 35.3M

Risk 3d forecast

Volatility26.7%

VaR 5^th Pctl4.28%

VaR vs Median-2.24%

Reward TTM

Sharpe Ratio-0.94

Rel. Str. IBD14.6

Rel. Str. Peer Group19.2

Character TTM

Beta-0.092

Beta Downside-0.069

Hurst Exponent0.477

Drawdowns 3y

Max DD29.70%

CAGR/Max DD0.27

CAGR/Mean DD0.78

EPS (Earnings per Share)

EPS CAGR: -6.13%
EPS Trend: -9.4%

Last SUE: 0.00
Qual. Beats: 0

Revenue

Rev. CAGR: 17.94%
Rev. Trend: 90.2%

Last SUE: 1.09
Qual. Beats: 1

Warnings

Below Sma 200d

Tailwinds

No distinct edge detected

Seasonality 11.7 years of data

Jan +1.2% 24

Feb -0.4% 2

Mar -1.8% 11

Apr +2.8% 28

May +1.5% 18

Jun +0.2% 7

Jul -1.8% 8

Aug +0.9% 5

Sep -1.5% 29

Oct -9.6% 31

Nov +1.0% 13

Dec +2.7% 15

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.

Description: SNN Smith & Nephew SNATS

Smith & Nephew plc, headquartered in Watford, United Kingdom, and founded in 1856, is a global medical device company operating across three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. Its orthopaedics portfolio includes knee and hip implants as well as trauma and extremities products, while its sports medicine line covers minimally invasive joint repair instruments, arthroscopic visualization and tissue resection technologies, and ENT solutions. The Advanced Wound Management segment provides wound care dressings, biologics and regenerative medicine products (including skin and bone graft substitutes), negative pressure wound therapy systems, and hydrosurgery devices.

The company serves healthcare providers in the United Kingdom, the United States, and internationally, and is classified within the Health Care Equipment sub-industry of the GICS Health Care sector. Medical device companies like Smith & Nephew typically operate a business model built around long product development cycles, regulatory approvals, and direct sales relationships with hospitals and surgical centers, which tend to create high barriers to entry and recurring revenue from consumables such as implants and wound dressings.

Headlines to Watch Out For

Orthopaedics pricing pressure from hospital systems compresses margins
Cevian Capital activist stake accelerates cost cuts and portfolio review
Sports Medicine joint repair growth outpaces rivals like Arthrex

Piotroski VR-10 (Strict) 7.0

Net Income: 635.0m TTM > 0 and > 6% of Revenue
FCF/TA: 0.08 > 0.02 and ΔFCF/TA 0.30 > 1.0
NWC/Revenue: 37.08% < 20% (prev 51.87%; Δ -14.79% < -1%)
CFO/TA 0.12 > 3% & CFO 1.34b > Net Income 635.0m
Net Debt (3.25b) to EBITDA (1.38b): 2.35 < 3
Current Ratio: 2.14 > 1.5 & < 3
Outstanding Shares: last quarter (430.4m) vs 12m ago -1.45% < -2%
Gross Margin: 68.44% > 18% (prev 70.59%; Δ -2.15% > 0.5%)
Asset Turnover: 58.08% > 50% (prev 55.64%; Δ 2.43% > 0%)
Interest Coverage Ratio: 6.91 > 6 (EBIT TTM 896.0m / Interest Expense TTM 129.7m)

Altman Z'' 4.49

A: 0.21 (Total Current Assets 4.39b - Total Current Liabilities 2.05b) / Total Assets 11.0b
B: 0.49 (Retained Earnings 5.43b / Total Assets 11.0b)
C: 0.08 (EBIT TTM 896.0m / Avg Total Assets 10.8b)
D: 0.89 (Book Value of Equity 5.18b / Total Liabilities 5.83b)
Altman-Z'' = 4.49 = AA

Beneish M -2.95

DSRI: 0.98 (Receivables 1.49b/1.44b, Revenue 6.30b/5.94b)
GMI: 1.03 (GM 70.59% / 68.44%)
AQI: 1.05 (AQ_t 0.46 / AQ_t-1 0.43)
SGI: 1.06 (Revenue 6.30b / 5.94b)
TATA: -0.06 (NI 635.0m - CFO 1.34b) / TA 11.0b)
Beneish M = -2.95 (Cap -4..+1) = A

What is the price of SNN shares?

As of October 08, 2026, the stock is trading at USD 26.89 with a total of 1,050,005 shares traded. Over the past week, the price has changed by +0.93%, over one month by -2.37%, over three months by -10.73% and over the past year by -22.69%.

Current recommended Stop Loss: 26.20 (which is 2.6% or 1.3 ATR below the current price).

Is SNN a buy, sell or hold?

Smith & Nephew SNATS has received a consensus analysts rating of 3.17. Therefore, it is recommended to hold SNN.

StrongBuy: 0
Buy: 1
Hold: 5
Sell: 0
StrongSell: 0

What are the forecasts/targets for the SNN price?

Analysts Target Price	32.7	21.7%

Smith & Nephew SNATS (SNN) - Fundamental Data Overview as of 05 October 2026

Market Cap USD = 11.1b (11.1b USD * 1.0 USD.USD)
P/E Trailing = 17.9728
P/E Forward = 11.1607
P/S = 1.7551
P/B = 2.2219
P/EG = 1.0515
Revenue TTM = 6.30b USD
EBIT TTM = 896.0m USD
EBITDA TTM = 1.38b USD
Long Term Debt = 3.03b USD (from longTermDebt, last fiscal year)
Short Term Debt = 573.0m USD (from shortTermDebt, last quarter)
Debt = 4.00b USD (from shortLongTermDebtTotal, last quarter) + Leases 216.0m
Net Debt = 3.25b USD (calculated: Debt 4.00b - CCE 754.0m)
Enterprise Value = 14.3b USD (11.1b + Debt 4.00b - CCE 754.0m)
Interest Coverage Ratio = 6.91 (Ebit TTM 896.0m / Interest Expense TTM 129.7m)
EV/FCF = 16.73x (Enterprise Value 14.3b / FCF TTM 855.0m)
FCF Yield = 5.98% (FCF TTM 855.0m / Enterprise Value 14.3b)
FCF Margin = 13.57% (FCF TTM 855.0m / Revenue TTM 6.30b)
Net Margin = 10.08% (Net Income TTM 635.0m / Revenue TTM 6.30b)
Gross Margin = 68.44% ((Revenue TTM 6.30b - Cost of Revenue TTM 1.99b) / Revenue TTM)
Gross Margin QoQ = 70.91% (prev 66.06%)
Tobins Q-Ratio = 1.30 (Enterprise Value 14.3b / Total Assets 11.0b)
Interest Expense / Debt = 3.24% (Interest Expense 129.7m / Debt 4.00b)
Taxrate = 20.33% (162.0m / 797.0m)
NOPAT = 713.9m (EBIT 896.0m * (1 - 20.33%))
Current Ratio = 2.14 (Total Current Assets 4.39b / Total Current Liabilities 2.05b)
Debt / Equity = 0.77 (Debt 4.00b / totalStockholderEquity, last quarter 5.18b)
Debt / EBITDA = 2.35 (Net Debt 3.25b / EBITDA 1.38b)
Debt / FCF = 3.80 (Net Debt 3.25b / FCF TTM 855.0m)
Total Stockholder Equity = 5.32b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.85% (Net Income 635.0m / Total Assets 11.0b)
RoE = 11.94% (Net Income TTM 635.0m / Total Stockholder Equity 5.32b)
RoCE = 10.74% (EBIT 896.0m / Capital Employed (Equity 5.32b + L.T.Debt 3.03b))
RoIC = 7.74% (NOPAT 713.9m / Invested Capital 9.22b)
WACC = 4.84% (E(11.1b)/V(15.1b) * Re(5.66%) + D(4.00b)/V(15.1b) * Rd(3.24%) * (1-Tc(0.20)))
Discount Rate = 5.66% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -64.08 | Cagr: -26.98%
[DCF] Terminal Value 76.35% ; FCFF base≈831.8m ; Y1≈885.6m ; Y5≈1.05b
[DCF] Fair Price = 30.97 (EV 16.2b - Net Debt 3.25b = Equity 13.0b / Shares 418.5m; r=8.35% [WACC [floored]]; 5y FCF grow 7.28% → 2.50% )
EPS Correlation: -9.43 | EPS CAGR: -6.13% | SUE: 0.0 | # QB: 0
Revenue Correlation: 90.21 | Revenue CAGR: 17.94% | SUE: 1.09 | # QB: 1
EPS current Quarter (2026-06-30): EPS=0.00 | Chg30d=N/A | Revisions=N/A | Analysts=0
EPS next Quarter (2026-09-30): EPS=0.53 | Chg30d=N/A | Revisions=+0% | Analysts=1
EPS current Year (2026-12-31): EPS=2.22 | Chg30d=+2.01% | Revisions=+25% | GrowthEPS=+9.0% | GrowthRev=+4.9%
EPS next Year (2027-12-31): EPS=2.41 | Chg30d=-0.69% | Revisions=-40% | GrowthEPS=+8.4% | GrowthRev=+5.3%
[Analyst] Revisions Ratio: -17% (up=1, down=2)